Market Intelligence, Clinical Progress, and High-Purity Reagents for Serotonin Receptor 2B Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HTR2B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Stable Line | HTR2B Lentivirus Premade Particles Full-length ORF for stable cell line generation. Perfect for functional GPCR assays. |
View HTR2B Products |
| Gene Delivery | HTR2B Promise-ORF / Plasmid Vector Sequence verified expression plasmid for transient or stable transfection. |
View HTR2B Products |
| Benchmark Ab | Anti-HTR2B Recombinant Antibody High affinity benchmark positive control for flow cytometry and binding validation. |
View HTR2B Products |
| Validator | HTR2B siRNA Set For target knockdown and specificity verification in cell-based assays. |
View HTR2B Products |
| Related Target A | HTR2A Critical counter-screening target. GPCR homolog used to verify off-target selectivity. |
View HTR2A Products |
| Related Target B | HTR2C Key safety and efficacy counter-screening target in CNS and metabolic pipelines. |
View HTR2C Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Native Conformation Preservation | Lentivirus for Stable Cell Line construction ensures native 7-transmembrane folding. |
| Subfamily Counter-Screening (HTR2A/2C) | Sequence-verified homolog plasmids and lentiviruses available for precise cross-reactivity profiling. |
| Lack of Controls | Recombinant positive control antibodies and validated siRNA sets included in the ecosystem. |
| High Background & False Positives | Endotoxin-controlled systems with sequence-verified open reading frames (ORFs). |
Live HTR2B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The serotonin receptor 2B (HTR2B) occupies a unique and dual-faceted position in modern drug discovery. Historically notorious as the primary mediator of drug-induced valvular heart disease (valvulopathy)—which led to the withdrawal of major therapeutics like fenfluramine—HTR2B has transitioned from a pure toxicology counter-screening target to an active therapeutic avenue. Today, the race for HTR2B therapeutics is intensifying, with major players shifting focus from traditional small molecules to highly selective antagonists and tissue-targeted modalities. As first-generation selective therapies reach the clinic, the next wave of R& R is targeting indications such as pulmonary arterial hypertension (PAH), irritable bowel syndrome (IBS), ocular diseases, and fibrotic cancers.
Competitive Modality & Indication Snapshot
Connecting market trends to assay needs:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | Pharmasum, Arena Pharmaceuticals | PAH, IBS, Fibrosis | Selectivity Assay (Need HTR2A/2C vs HTR2B stable cell lines to confirm lack of cross-activation) |
| Monoclonal Antibodies | Academic institutions, Biotech startups | Oncology, Fibrotic Diseases | Surface binding validation (Need Lentivirus-driven stable cells for flow cytometry) |
| CNS Safety Profiling | Global Pharma (AstraZeneca, Lilly) | Obesity, Depression (Safety Panel) | High-throughput FLIPR/Calcium Flux counter-screening (Requires robust HTR2B expressing cell lines) |